POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)

The Associated Press reported that POP Biotechnologies, founded by Jonathan Lovell, completed a study on a new recombinant COVID vaccine, EuCorVac-19.